Orasis Pharmaceuticals Launches Qlosi Starter Packs to Expand Patient Access

Orasis Pharmaceuticals has announced the nationwide rollout of Starter Packs for Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, its FDA-approved treatment for presbyopia. Designed to broaden access and support clinical adoption, the Starter Packs aim to provide eye care professionals (ECPs) with a practical tool for initiating treatment in appropriate patients.

The new initiative builds on the company’s successful commercial launch of Qlosi in the United States in April 2025 and reflects growing demand and high patient satisfaction. Orasis reports that refill rates have exceeded expectations, with no serious adverse events reported since market entry.

“Orasis remains deeply committed to redefining how people think about presbyopia treatment—moving beyond the limitations of reading glasses,” said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals.
“This year alone, our direct-to-consumer campaigns have generated over one million clicks from individuals seeking information about Qlosi. With the introduction of Starter Packs, we’re building on significant momentum, and as we look ahead to 2026, we are positioned to expand our outreach to even more people seeking clearer near vision.”

Starter Pack Details and Distribution

Each Qlosi Starter Pack includes:

       • 10 single-use vials (two daily doses for five days)

       • A patient progress tracker

       • A referral card

These materials are delivered directly to prescribing ECPs to ensure seamless integration into the clinical workflow and to support early patient experience with Qlosi.